# Werewolf Therapeutics, Inc. (HOWL) — divestiture/asset_sale [announced]
Source: SEC API (secapi.ai) · situation sit_3ee58d86569f8a136097 · retrieved 2026-08-11T15:54:04.916Z

## Overview
Werewolf Therapeutics is a biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions.

Werewolf Therapeutics sold its JZP898 program to Jazz Pharmaceuticals Ireland Limited and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. The combined transactions generated $21.0 million in proceeds to Werewolf. The company is conducting a strategic alternatives review with exclusive financial advisor Piper Sandler & Co. to explore multiple options for continued development of its INDUKINE and INDUCER platforms.

## Terms
- Counterparty: Jazz Pharmaceuticals Ireland Limited · Deal value: $21.0M · Consideration: cash

## Key dates
- Announced 2026-07-31

## Timeline
- 2026-07-31 · 8-K (0001785530-26-000018): 8-K - Werewolf Therapeutics, Inc. — *Werewolf Therapeutics is a biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions.* Werewolf Therapeutics sold its JZP898 program to Jazz Pharmaceuticals Ireland Limited and repaid all amounts owed under its loan and security agreement with K2 HealthVentures LLC. The combined transactions generated $21.0 million in proceeds to Werewolf. The company is conducting a strategic alternatives review with exclusive financial advisor Piper Sandler & Co. to explore multiple options for continued development of its INDUKINE and INDUCER platforms.
  https://www.sec.gov/Archives/edgar/data/1785530/0001785530-26-000018.txt

## Citations
- 0001785530-26-000018 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000178553026000018